Any myostatin inhibitor FDA approved by 2027
4
Ṁ1172026
63%
chance
1D
1W
1M
ALL
This market predicts whether any myostatin inhibitor will receive regulatory approval for any condition by December 31, 2026. Myostatin inhibitors are being developed to treat conditions like muscular dystrophy and obesity. Notable candidates include Regeneron's trevogrumab and Eli Lilly's bimagrumab. Approval status can be verified through official regulatory agency announcements, such as those from the FDA (https://www.fda.gov/).
This question is managed and resolved by Manifold.
Get
1,000and
3.00
1,0003.00Related questions
Related questions
Mazdutide approved in US in 2025
38% chance
Will I get follistatin gene therapy by EOY 2026?
29% chance
Will Retatrutide (new obesity drug) be FDA approved by the end of 2025?
19% chance
Will FDA approve any mRNA vaccine against mesothelioma before 2028?
30% chance
Will FDA approve any mRNA vaccine against stomach adenocarcinoma before 2028?
31% chance
Which of these protein targets will have at least one new drug targeting them receive FDA approval between 2025 and 2030
Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?
62% chance
Will FDA approve any mRNA vaccine against pancreatic adenocarcinoma before 2028?
19% chance
Will FDA approve any mRNA vaccine against prostate adenocarcinoma before 2028?
41% chance
Will FDA approve any mRNA vaccine against esophageal adenocarcinoma before 2028?
33% chance